Pyrimethamine (Synonyms: Pirimecidan; Pirimetamin; RP 4753)

Name: Pyrimethamine
Brand: MedChemExpress
SKU: HY-18062
Rating: 5.0 (13 reviews)

Cat. No.: HY-18062 Purity: 99.99%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Pyrimethamine (Pirimecidan) is a potent, orally active dihydrofolate reductase (DHFR) inhibitor. Pyrimethamine is an antimalarial agent. Pyrimethamine affects the nucleoprotein metabolism of malarial parasites by interference in the folic–folinic acid systems and affects cell division by inhibiting the conversion of dihydrofolate to tetrahydrofolate.

For research use only. We do not sell to patients.

CAS No. : 58-14-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Pyrimethamine:

Pyrimethamine-d₃ In-stock
Pyrimethamine (Standard) Get quote

13 Publications Citing Use of MCE Pyrimethamine

Cell Proliferation/Viability Assay

: Pyrimethamine purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Jun;17(6):1325-1354. [Abstract]; Cell viability assay of patient-derived GICs and GICRs, treated with increasing concentrations of Pyrimethamine.

: Pyrimethamine purchased from MedChemExpress. Usage Cited in: Biomolecules. 2025 Feb 1;15(2):202.; Antiproliferative effect of Pyrimethamine (PYR: 10 μM) on intracellular Toxoplasma gondii, cellular immunofluorescence image.

: Pyrimethamine purchased from MedChemExpress. Usage Cited in: J Lipid Res. 2024 Oct 25:100684. [Abstract]; H-RFP were cultured in the presence of AY9944 (5 μM) or Pyrimethamine (PYR: 10 μM) in 96-well plates for 24 h.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Plasmodium

Cellular Effect

Cell Line	Type	Value	Description	References
BC	IC₅₀	40 μM Compound: Pyrimethamine (P1)	In vitro cytotoxicity against Plasmodium falciparum infected BC cell line. In vitro cytotoxicity against Plasmodium falciparum infected BC cell line.	[PMID: 14736247]
BC	IC₅₀	> 250 μM Compound: Pyr	Cytotoxicity against human breast cancer cells. Cytotoxicity against human breast cancer cells.	[PMID: 11881993]
CHO	IC₅₀	271 μM Compound: PM	Cytotoxicity against CHO cells after 48 hrs by MTT assay Cytotoxicity against CHO cells after 48 hrs by MTT assay	[PMID: 24602791]
Erythrocyte	IC₅₀	0.004 μM Compound: Pyrimethamine	Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay	[PMID: 36561069]
HEK293	CC₅₀	>= 20 μM Compound: Pyrimethamine	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	[PMID: 30537832]
HEK293	IC₅₀	0.69 μM Compound: Pyrimethamine	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	[PMID: 29236492]
HEK293	IC₅₀	13.57 μM Compound: Pyrimethamine	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	[PMID: 28230985]
HEK293	IC₅₀	4.2 μM Compound: Pyrimethamine	Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay	[PMID: 28001067]
HEK293	IC₅₀	4.2 μM Compound: Pyrimethamine	Cytotoxicity against HEK293 cells Cytotoxicity against HEK293 cells	[PMID: 32067457]
HEK293	IC₅₀	4.22 nM Compound: Pyrimethamine	Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis	[PMID: 26651537]
HEK293	IC₅₀	8.07 nM Compound: Pyrimethamine	Cytotoxicity against HEK293 cells by alamar blue assay Cytotoxicity against HEK293 cells by alamar blue assay	[PMID: 27212070]
HEK293	IC₅₀	> 10 μM Compound: Pyrimethamine	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay	[PMID: 36799121]
HEL	IC₅₀	0.67 μM Compound: Pyrimethamine	The ability to inhibit [3H]- uracil incorporation by Toxoplasma gondii in cultures of HEL cells was tested The ability to inhibit [3H]- uracil incorporation by Toxoplasma gondii in cultures of HEL cells was tested	[PMID: 10090784]
HEL	IC₅₀	0.7 μM Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii infected in HEL cells assessed as inhibition of parasite growth by [3H]uracil incorporation assay Antimicrobial activity against Toxoplasma gondii infected in HEL cells assessed as inhibition of parasite growth by [3H]uracil incorporation assay	[PMID: 20117005]
HFF	CC₅₀	> 50 μM Compound: Pyrimethamine	Cytotoxicity against human HFF cells after 72 hrs by MTT assay Cytotoxicity against human HFF cells after 72 hrs by MTT assay	[PMID: 21741131]
HFF	CC₅₀	> 50 μM Compound: Pyrimethamine	Cytotoxicity against HFF assessed as cell proliferation after 96 hrs by alamar blue reduction assay Cytotoxicity against HFF assessed as cell proliferation after 96 hrs by alamar blue reduction assay	[PMID: 26479029]
HFF	EC₅₀	0.21 μM Compound: Pyrimethamine	Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	0.24 μM Compound: Pyrimethamine	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	0.27 μM Compound: Pyrimethamine	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	0.29 μM Compound: Pyrimethamine	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	IC₅₀	0.8 μM Compound: Pyrimethamine	Antitoxoplasmic activity against Toxoplasma gondii PRU tachyzoites infected in human HFF cells assessed as beta-galactosidase activity after 72 hrs by colorimetric assay Antitoxoplasmic activity against Toxoplasma gondii PRU tachyzoites infected in human HFF cells assessed as beta-galactosidase activity after 72 hrs by colorimetric assay	[PMID: 22608675]
HFF	IC₅₀	1.1 μM Compound: Pyrimethamine	Antiparasitic activity against Toxoplasma gondii PRU tachyzoites harboring beta-Gal gene infected in human HFF cells after 72 hrs by microtiter plate based assay Antiparasitic activity against Toxoplasma gondii PRU tachyzoites harboring beta-Gal gene infected in human HFF cells after 72 hrs by microtiter plate based assay	[PMID: 21741131]
HeLa	EC₅₀	0.75 μM Compound: 32	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
HeLa	EC₅₀	> 100 μM Compound: 32	Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
HeLa	EC₅₀	> 100 μM Compound: 32	Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
HepG2	CC₅₀	7.1 μM Compound: Pyrimethamine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21741131]
HepG2	CC₅₀	7.1 μM Compound: Pyrimethamine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22608675]
HepG2	IC₅₀	0.0047 μM Compound: 92125099	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	[PMID: 22586124]
HepG2	IC₅₀	1.03 μM Compound: 76	Antimalarial activity against liver stages of Plasmodium cynomolgi infected in human HepG2 cells assessed as growth inhibition of hepatic parasite after 3 days Antimalarial activity against liver stages of Plasmodium cynomolgi infected in human HepG2 cells assessed as growth inhibition of hepatic parasite after 3 days	[PMID: 22122518]
HepG2	IC₅₀	30 μM Compound: Pyrimethamine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19482476]
HepG2	IC₅₀	< 1 μM Compound: Pyrimethamine	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	[PMID: 23927658]
HepG2	IC₅₀	> 10 μM Compound: 92125099	HARVARD: Cytotoxicity in HepG2 cell line HARVARD: Cytotoxicity in HepG2 cell line	[PMID: 22586124]
Huh-7	CC₅₀	45.62 μM Compound: GNF-Pf-5586	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
K562	IC₅₀	5 μM Compound: Pyrimethamine	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19482476]
KB	IC₅₀	109 μM Compound: Pyr	Cytotoxicity against human epidermoid carcinoma KB cell. Cytotoxicity against human epidermoid carcinoma KB cell.	[PMID: 11881993]
KB	IC₅₀	109 μM Compound: Pyrimethamine (P1)	In vitro cytotoxicity against Plasmodium falciparum infected KB cell line In vitro cytotoxicity against Plasmodium falciparum infected KB cell line	[PMID: 14736247]
MCF7	EC₅₀	11700 nM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30624926]
MCF7	IC₅₀	453 μM Compound: PYM	Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
MDA-MB-231	IC₅₀	238 μM Compound: PYM	Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay	[PMID: 32061484]
MDCK	CC₅₀	41 μM Compound: 32	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	[PMID: 28477572]
MRC5	ED₅₀	16.23 μg/mL Compound: 1	Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay	[PMID: 21126022]
MRC5	ED₅₀	16.2 μg/mL Compound: PYR	Toxicity against human MRC5 cells assessed as growth inhibition Toxicity against human MRC5 cells assessed as growth inhibition	[PMID: 22946585]
MRC5	IC₅₀	0.07 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.09 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.09 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.11 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.11 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.12 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.14 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.15 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.17 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.18 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.19 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.1 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.25 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.34 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.35 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.39 mg/L Compound: Pyrimethamine	Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
Vero	CC₅₀	122 μM Compound: Pyr	Cytotoxicity against African green monkey Vero cells after 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 24 hrs by MTT assay	[PMID: 25899334]
Vero	CC₅₀	18.12 μM Compound: Pyrimethamine	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 37163950]
Vero	EC₅₀	20 μM Compound: 32	Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	46 μM Compound: 32	Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	5.4 μM Compound: 32	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	8.9 μM Compound: 32	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	> 100 μM Compound: 32	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	> 100 μM Compound: 32	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	IC₅₀	18.2 μM Compound: 2	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 24900509]
Vero	IC₅₀	32 μM Compound: PYR	Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay	[PMID: 31685330]
Vero	IC₅₀	32 μM Compound: Pyr	Cytotoxicity by the selective inhibition against African green monkey kidney fibroblast (vero cells). Cytotoxicity by the selective inhibition against African green monkey kidney fibroblast (vero cells).	[PMID: 11881993]
Vero	IC₅₀	32 μM Compound: Pyrimethamine (P1)	In vitro cytotoxicity against Plasmodium falciparum infected vero cell line. In vitro cytotoxicity against Plasmodium falciparum infected vero cell line.	[PMID: 14736247]
Vero	IC₅₀	> 6.25 μg/mL Compound: Pyrimethamine	Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28552337]
Vero	IC₅₀	> 62.5 μg/mL Compound: Pyrimethamine	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23352268]

In Vitro

Pyrimethamine (Pirimecidan; 4 nM-4 μM; 24 h; LLC-MK2 cells with T. gondii) combination of Fluconazole (FLZ) (HY-B0101) inhibits T. gondii activity with IC₅₀ values of 0.23, 0.19, 0.23, 0.34, 0.14, and 0.19 μM for FLZ concentration at 0, 0.05, 0.1, 0.5, 1.0, and 3.0 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	LLC-MK2 cells with T. gondii
Concentration:	4 nM-4 μM
Incubation Time:	24 hours
Result:	Inhibited T. gondii activity and decreased parasite proliferation index.

In Vivo

Pyrimethamine (Pirimecidan; 1 mg/kg; i.g.; daily, for 10 d; female CF1 mice with T. gondii xenograft) combination of Fluconazole (HY-B0101) and Sulfadiazine (HY-B0273) increases protection from death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CF1 mice (18-22 g; 4-6 week of age) with T. gondii xenograft^[1]
Dosage:	Oral gavage; daily, for 10 days
Administration:	1 mg/kg; 10 mg/kg (Fluconazole (HY-B0101)), 40 mg/kg (Sulfadiazine (HY-B0273))
Result:	Increased mouse survival compared to treatment with SDZ/PYR alone.

Clinical Trial

Molecular Weight

248.71

Formula

C₁₂H₁₃ClN₄

CAS No.

58-14-0

Appearance

Solid

Color

White to off-white

SMILES

NC1=NC(N)=C(C2=CC=C(Cl)C=C2)C(CC)=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL (80.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.0207 mL	20.1037 mL	40.2075 mL
5 mM	0.8041 mL	4.0207 mL	8.0415 mL
10 mM	0.4021 mL	2.0104 mL	4.0207 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% PBS
Solubility: 25 mg/mL (100.52 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.99%

Select Batch:

Data Sheet (278 KB) SDS (480 KB)

COA (249 KB) HNMR (117 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Aikawa M, et, al. Studies on nuclear division of a malarial parasite under pyrimethamine treatment. J Cell Biol. 1968 Dec;39(3):749-54. [Content Brief]

[2]. Martins-Duarte ÉS, et, al. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. Exp Parasitol. 2013 Mar;133(3):294-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.0207 mL	20.1037 mL	40.2075 mL	100.5187 mL
	5 mM	0.8041 mL	4.0207 mL	8.0415 mL	20.1037 mL
	10 mM	0.4021 mL	2.0104 mL	4.0207 mL	10.0519 mL
	15 mM	0.2680 mL	1.3402 mL	2.6805 mL	6.7012 mL
	20 mM	0.2010 mL	1.0052 mL	2.0104 mL	5.0259 mL
	25 mM	0.1608 mL	0.8041 mL	1.6083 mL	4.0207 mL
	30 mM	0.1340 mL	0.6701 mL	1.3402 mL	3.3506 mL
	40 mM	0.1005 mL	0.5026 mL	1.0052 mL	2.5130 mL
	50 mM	0.0804 mL	0.4021 mL	0.8041 mL	2.0104 mL
	60 mM	0.0670 mL	0.3351 mL	0.6701 mL	1.6753 mL
	80 mM	0.0503 mL	0.2513 mL	0.5026 mL	1.2565 mL

Pyrimethamine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pyrimethamine58-14-0Pirimecidan Pirimetamin RP 4753RP4753RP 4753RP-4753AntifolateParasiteantimalarialnucleoprotein metabolismfolic–folinic acid systemsparasitescell divisionInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Pyrimethamine (Synonyms: Pirimecidan; Pirimetamin; RP 4753)

Customer Review

Other Forms of Pyrimethamine:

Pyrimethamine Related Antibodies

13 Publications Citing Use of MCE Pyrimethamine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Pyrimethamine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Pyrimethamine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report